Walgreens, Alignment partner on co-branded MA plans
The zero-dollar premium plans will be available in 10 counties in Arizona, California, Florida and Texas starting next year.
Walgreens, Alignment partner on co-branded MA plans Read More »
The zero-dollar premium plans will be available in 10 counties in Arizona, California, Florida and Texas starting next year.
Walgreens, Alignment partner on co-branded MA plans Read More »
The company will work with the Global Fund to Fight AIDS, Tuberculosis and Malaria, providing free licenses and helping to integrate AI-enabled processes into clinicians’ workflows.
Siemens Healthineers partners to improve tuberculosis screening using AI Read More »
The incident affected a portion of the company’s manufacturing and distribution businesses.
Sales of the FreeStyle Libre continuous glucose monitor rose nearly 31% despite investor worries about the potential impact of weight-loss drugs on demand.
Abbott raises outlook amid strong Q3, sees momentum into 2024 Read More »
The average premium was nearly $8,500 for single coverage and nearly $24,000 for family coverage this year, according to a new study published in Health Affairs.
Premiums rose 7% for employer-sponsored health coverage in 2023 Read More »
The insurer is actively seeking ways to mitigate the financial impact of its star ratings drop, Elevance CEO Gail Boudreaux said during the insurer’s third-quarter earnings call.
Elevance could see $500M quality bonus revenue hit in 2025 from MA star ratings drop Read More »
The incident affected a portion of the medical supply company’s manufacturing and distribution businesses.
The collaborators assessed the feasibility of recycling medical waste such as plastic syringes.
BD recycles 40,000 pounds of medical waste in circular economy pilot project Read More »
Traverse Biotech, Inc announced today that the National Cancer Institute (NCI) of the National Institutes of Health has awarded them a Small Business Innovation Research (SBIR) Phase 1 Grant to fund the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC).
Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023.